• 1ST BIO
  • Turning Breakthrough
  • Discoveries  into Medicines

About Us

About Us

1ST Bio is dedicated to developing breakthrough therapies with a key value to provide novel medicines to patients. We are focused on discovery and development of innovative first-in-class therapeutic candidates with highly likelihood of clinical success. 1ST Bio currently has 23 employees with expertise in biochemistry, medicinal chemistry, pharmacology, and business development. We are working as a core expertise team of drug discovery/development and are rigorously connected to R&D networking of academia, hospitals, industry, CRO’s and investors in Korea, China and US. Our ultimate goal is to use our experience and knowledge to discover and develop effective molecular therapeutics for patients.

Management

Management

CEO and Founder
Jamie Jae Eun Kim, Ph.D.


Jamie Jae Eun Kim has founded 1ST Biotherapeutics, Inc. in 2016 and has been served as CEO since then, bringing a wealth of scientific leadership and business expertise. She has been engaged in all aspects of drug discovery and development as well as business development, with a particular focus on cancers, metabolic diseases and orphan diseases. Jamie has deep experience brokering R&D strategies and portfolio management in pharma R&D, with track record of over 50 successful R&D alliances among biotech, academia, clinical research units and industry throughout her career. Previously, Jamie was Director of the Biotherapeutics Research Center at Handok, where she was responsible for several development programs in oncology and rare diseases and for research alliance and investment. She was an Associate Director at Green Cross Corp. (Now GC Pharma), where she has newly established a discovery team in oncology and rare diseases, and, prior to that, she was a Collaboration Project Leader at Sanofi, leading collaborative research effort in oncology. Jamie spent her early career doing metabolic and oncology research leading discovery projects as a Senior Scientist at Wyeth in Pearl River, NY. She is a current member of the Global Pharma Key Opinion Leader (GPKOL) consultants and a former member of the Korea Drug Development Fund (KDDF) investment committee. Jamie has a bachelor’s in bioengineering and master’s degree in biological science from KAIST (Korea Advanced Institute of Science and Technology). she graduated with a Ph.D. in cell and structural biology from the University of Illinois at Urbana Champaign, USA.

Chief Technology Officer
Jinhwa Lee, Ph.D.


Jinhwa Lee has an accomplished career in drug discovery spanning academia and industry. He has helped identify and advance novel anti-bacterials, anti-virals, anti-coagulants, and therapies for metabolic syndrome, CNS disorders, and cancer. To date, he has authored 57 scientific papers and has been awarded 37 international and domestic patents. Prior to joining 1ST Biotherapeutics, Jinhwa served as Director of the New Drug Research Center and acting Director of the Biotherapeutics Research Center at Handok. He was served as Director of the Late Discovery Program at Institut Pasteur Korea (IP-K) and prior to that, as Head of Medicinal Chemistry group at Green Cross Corporation (now, GC Pharma), leading many of drug discovery/development programs and their advancement into preclinical/clinicals stages in oncology, metabolic diseases, and infectious diseases. Jinhwa was Senior Investigator at GlaxoSmithKline in Collegeville, PA, where he also earned a five -year service appreciation award. Jinhwa has a bachelor’s and master’s degree from Seoul National University. He achieved a Ph.D. in chemistry from the University of Alabama and completed his postdoctoral research at Harvard University.

Senior Advisor
Jin-Keon Pai, Ph.D.


Jin-Keon Pai joined 1st Biotherapeutics as a Senior Advisor in early 2018. He brings significant scientific and strategic expertise, honed over 24 years as a scientist with the Schering-Plough Research Institute, a subsidiary of Schering-Plough Corporation (now part of Merck & Co). Most recently, Jin-Keon was served as a Senior Advisor at Handok and as Chair of the Central Research Institute and Executive Vice President at Choongwae Pharma Corp. He is widely respected, serving on the Scientific Advisory Boards of ABL Therapeutics, InterVest Global Fund, LSK Fund and, formerly, Institut Pasteur Korea (IP-K). He was a former member of the Investment Committee for the Korean Drug Development Fund (KDDF). Jin-Keon earned a B.S. in biochemistry from Yonsei University and a Ph.D. in pharmaceutical biochemistry from the University of Wisconsin-Madison. He is a member of the American Association of Cancer Research, American Association for the Advancement of Science, New York Academy of Science, and the Society of Biomedical Research.

Scientific Advisory Board

Scientific Advisory Board

Phil Hyu Lee, M.D., Ph.D.

Phil Hyu Lee is a practicing neurologist and Professor at Yonsei University’s Department of Neurology and Severance Biomedical Science Institute. He is an expert on Parkinson’s disease and has been recognized as a top Young Investigator by the Korean Neurological Association and the Korean Movement Disorders Society. Phil is first or corresponding author on more than 100 peer-reviewed papers and serves on the editorial board of the Journal of Clinical Neurology.

Eui-Cheol Shin, M.D., Ph.D.

Eui-Cheol Shin is Professor and Endowed Chair Professor at the Graduate School of Medical Science & Engineering at KAIST. Eui-Cheol is Chair of the Korean Association of Immunologists’ Vaccine Interest Group. He serves on the academic committee for the Korean Vaccine Society and is a member of the immunology working group for the International Coalition to Eliminate Hepatitis B Virus (ICE-HBV). He also sits on the editorial boards of Frontiers in Microbiology, PLoS One, Clinical and Experimental Medicine, Immune Network, and is Associate Editor of Clinical and Experimental Vaccine Research.

Ae Nim Pae, Ph.D.

Ae Nim Pae heads the Convergence Research Center for Diagnosis, Treatment and Care System of Dementia (DTC) at the Korea Institute of Science and Technology (KIST). She oversees both basic research and drug discovery for Alzheimer’s disease and dementia; conditions that are becoming and more and more prevalent with the aging of developed nations, but that still lack effective treatments. Prior to joining the Convergence Research Center in 2012, Ae Nim was the Head of the KIST Center for Neuro-Medicine. She is widely published in top journals and has received a Ministry of Science and ICT award, a Presidential Award (Korea), and a Prime Minister Award (Korea) for her scientific achievement.

Therapeutic Focus

Therapeutic Focus

Neurodegenerative Diseases

Immuno-Oncology

Orphan diseases

pipeline

pipeline


1ST-102 targets c-Abl, which has been shown to play a critical role in driving alpha-synuclein pathogenesis in Parkinson’s disease. Our current candidate has optimal properties as CNS drug with potent neuroprotection activities and desirable safety profiles. We expect to file phase I IND in 2018 and we believe that it will be the first c-Abl inhibitor to advance into clinical trials, with optimal target engagement, CNS behaviors and safety profiles necessary for treatment of Parkinson’s disease with high potential as disease-modifying agent.

1ST-101 and 1ST-103 are in discovery stage as approaches to inhibit neuroinflammation associated with various neurodegenerative diseases. 1ST-101 and 1ST-103 block a critical pathway in vicious inflammatory response followed by neurotoxicity, which leads to disease-modifying potential and broad-spectrum therapeutic options for Parkinson’s, Alzheimer’s and ALS.

1ST-201 targets a crucial pathway in immuno-oncology and aims to reverse the active immune suppression and stimulate functionality of effector immune cells and dendritic cells in tumor microenvironment. We envision that 1ST-201 will provide novel therapeutic option as well as beneficial part of combination in immunotherapy with the objective of modulating multiple therapeutic opportunities for maximum benefits to cancer patients.

news

news

美뉴랄리와 파킨슨치료제 공동개발 협약

뉴랄리에서 후보물질에 대한 전임상 동물실험 진행…내년 FDA 임상승인 신청 목표

2018년 04월 30일0 comment

시리즈B 190억 유치

파킨슨병 치료제 후보물질 및 후속 프로젝트 연구개발에 투입, 면역항암제 특화된 자회사 티오바이오(TIO...

0 comment

COMPUTING BRAIN ENTRY

BioCentury reprint from January 22, 2018 COMPUTING BRAIN ENTRY Emerging Company Profile...

2018년 02월 15일0 comment

CONTACT US

CONTACT US

Let's Fulfill Unmet Medical Needs Together!

주식회사 퍼스트바이오 테라퓨틱스

경기도 성남시 분당구 판교역로 240 (삼환하이펙스 A동)

313호 (본사)

306호 (연구소)

 

1ST Biotherapeutics, Inc.

240 Pangyoyeok-ro, Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea

Suite 313 (HQ)

Suite 306 (R&D)

 

(031) 8023-5332 Main 
(031) 8023-5333 Fax